Cargando…

The Clinical Development of Levodopa Inhalation Powder

Oral levodopa is the most effective treatment for Parkinson disease, but OFF periods emerge over time. Gastrointestinal dysfunction and food effects impact levodopa absorption, contributing to unpredictable control of OFF periods. Inhaled levodopa powder (Inbrija) is approved for on-demand treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hauser, Robert A., LeWitt, Peter A., Waters, Cheryl H., Grosset, Donald G., Blank, Burkhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010694/ https://www.ncbi.nlm.nih.gov/pubmed/36715241 http://dx.doi.org/10.1097/WNF.0000000000000540

Ejemplares similares

Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease
por: LeWitt, Peter A., et al.
Publicado: (2018)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
por: LeWitt, Peter A., et al.
Publicado: (2022)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease
por: Luinstra, Marianne, et al.
Publicado: (2019)

Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2018)

IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease: The RISE-PD Randomized Clinical Trial
por: Hauser, Robert A., et al.
Publicado: (2023)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls
por: LeWitt, Peter A, et al.
Publicado: (2019)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Norepinephrine: the next therapeutics frontier for Parkinson's disease
por: LeWitt, Peter A
Publicado: (2012)

Spray Dried Levodopa-Doped Powder Potentially for Intranasal Delivery
por: Liu, Xuan, et al.
Publicado: (2022)

Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date
por: Patel, Ami B, et al.
Publicado: (2018)

Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
por: Sahakijpijarn, Sawittree, et al.
Publicado: (2020)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Subcutaneous Levodopa Infusion for Parkinson's Disease: 1‐Year Data from the Open‐Label BeyoND Study
por: Poewe, Werner, et al.
Publicado: (2021)

Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease
por: Martinez-Nunez, Alfonso E., et al.
Publicado: (2023)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
por: Gauani, Helena, et al.
Publicado: (2023)

Development of Chitosan-based Dry Powder Inhalation System of Cisplatin for Lung Cancer
por: Singh, D. J., et al.
Publicado: (2012)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development
por: Mohan, Abhinav Ram, et al.
Publicado: (2022)

Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles
por: Varshosaz, Jaleh, et al.
Publicado: (2017)

Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022)

Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers
por: de Reus, Y. A., et al.
Publicado: (2022)

Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

Effect of compression pressure on inhalation grade lactose as carrier for dry powder inhalations
por: Raut, Neha Sureshrao, et al.
Publicado: (2016)

Appropriate use of a dry powder inhaler based on inhalation flow pattern
por: Kondo, Tetsuri, et al.
Publicado: (2017)

Dry powder inhaled compound delivery for early pre-clinical in vivo efficacy studies
por: Ives, Robert, et al.
Publicado: (2013)

Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide
por: Debnath, Sujit Kumar, et al.
Publicado: (2018)

Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment
por: Lee, Wing-Hin, et al.
Publicado: (2020)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Clinical recommendations for dry powder inhaler use in the management of COPD in primary care
por: Leving, Marika T., et al.
Publicado: (2022)

PNPLA6‐Related Disorder with Levodopa‐Responsive Parkinsonism
por: Kazanci, Serdar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_431phguqebld108k1avh21r8gr